FDA approves Lilly's Inluriyo-Verzenio combo in oral SERD push
Eli Lilly's oral SERD Inluriyo is now approved in combination with Verzenio, a move that escalates competition among oral SERD therapies.
The FDA has approved Eli Lilly's oral SERD Inluriyo in combination with its cancer drug Verzenio, according to Fierce Pharma. The approval adds a new combination option in the oral SERD space and intensifies the competitive landscape in that drug class.
The approval follows data showing the combination delivered longer progression-free survival than oral SERD monotherapy. Jake Van Naarden, president of Lilly Oncology, told Fierce Pharma he expects most patients to select the combination over single-agent treatment.
Because this article draws on a single source, there is no conflicting account to compare. The reported outcome and the company's expectation are presented as stated in Fierce Pharma's coverage.
More in Medicine & Biotech
Ebola Vaccine Trial Launches in DR Congo Outbreak Zone
Health workers in DR Congo have begun testing whether a vaccine designed for a different Ebola strain can protect against the current outbreak.
Beacon Gene Therapy for Rare Vision Loss Succeeds in Pivotal Trial
A pivotal trial of Beacon Therapeutics' gene therapy for X-linked retinitis pigmentosa improved visual acuity, clearing the path toward an FDA submission.
Alkermes orexin agonist shows early promise for ADHD
Early-stage data suggest Alkermes' orexin agonist could expand the drug class beyond sleep disorders into ADHD.
Telix to Buy ITM for $1.65B, Challenging Novartis in Radiopharma
The acquisition gives Telix a late-stage pipeline and supply network that could compete with Novartis' Lutathera.